Form 4: Axogen Director Joseph Tyndall Sells Over 2,500 Shares of Common Stock

Axogen, Inc. Director Joseph A. Tyndall reported the sale of 2,525 shares of common stock at a price of $11.63 per share, reducing his direct beneficial ownership to 22,557 shares.

Summary

• Joseph A. Tyndall, a Director of Axogen, Inc. (AXGN), sold 2,525 shares of the company's common stock.
• The transaction occurred on May 19, 2025, with shares sold at a price of $11.63 per share.
• Following this sale, Mr. Tyndall directly beneficially owns 22,557 shares of Axogen, Inc. Common Stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale, which can sometimes be interpreted as a lack of confidence, although the transaction size is relatively small compared to total outstanding shares.

Negatives

• A director selling shares can sometimes be interpreted as a signal of reduced confidence in the company's near-term prospects, or a desire to diversify holdings.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It is specific to the trading activity of a director at Axogen, Inc., a company operating in the medical device or regenerative medicine sector.

Related Party Transactions

• The reported transaction is a related party transaction, as it involves the sale of company stock by a director, Joseph A. Tyndall.

Stakeholder Impact

• Shareholders may view the director's sale as a slight negative signal, potentially impacting investor confidence in the short term, though the impact is likely minimal given the transaction size.

Key Dates

Recommendation

Keywords

Axogen, AXGN, Joseph Tyndall, Insider Sale, Director Transaction, SEC Form 4, Common Stock, Share Sale